CTX110
- Generic Name
- CTX110
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.
- Associated Conditions
- -
- Associated Therapies
- -
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Phase 1
Terminated
- Conditions
- Non-Hodgkin LymphomaB-cell LymphomaAdult B Cell ALLB-cell Malignancy
- Interventions
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 62
- Registration Number
- NCT04035434
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
🇦🇺Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath